SPRO

Spero Therapeutics, Inc.

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$1

Price (1 Year)

$2.85 $1

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0.1 / %30
Non-compliant assets / Total market cap %54.3 / %30
Non-compliant revenue / Total income %73.4 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.

Website

Analysis (Turkish): SPRO Hissesi Caiz mi, Helal mi? Spero Therapeutics, Inc. Katılım Analizi